» Articles » PMID: 36314077

The Burden and Predictors of Venous Thromboembolic Diseases in Patients with Multiple Primary Malignancies

Overview
Specialty Oncology
Date 2022 Oct 31
PMID 36314077
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Venous thromboembolism (VTE) represents a considerable burden on cancer patients' survival and quality of life, but this burden varies based on the patient's baseline characteristics and cancer-related factors. Although solid evidence on the predictors and effect of VTE in cancer patients exists.

Aim: To evaluate VTE rate, morbidity, and mortality to develop parameters that could predict VTEs and their associated mortality in patients with multiple primary malignancies (MPMs).

Method And Results: This was a retrospective cohort study that took place at King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia. Two hundred and forty-two patients with at least two biopsy-proven malignancies and had at least 3 months of follow-up after MPMs diagnosis were included. VTE was diagnosed in 14.5% of the cases, two-thirds of which were deep vein thrombosis. VTE was significantly associated with a higher mortality and worse survival. Predictors of VTE after MPMs diagnosis were a high ECOG performance status at MPMs diagnosis, a metastatic first primary malignancy, and ICU admission after MPMs diagnosis. Having a GI or hematological malignancy as the second primary malignancy, a high D-dimer at ICU admission, and palliative care referral were significantly associated with a higher mortality in patients who had VTE.

Conclusion: VTE was diagnosed in 14.5% of patients with MPMs and it significantly compromises their survival. We believe that these results might be of particular benefit since the phenomenon of MPMs is becoming more frequently encountered.

Citing Articles

Blood hypercoagulability and thrombosis mechanisms in cancer patients -A brief review.

Peng Q, Zhu J, Zhang Y, Jing Y Heliyon. 2024; 10(19):e38831.

PMID: 39435109 PMC: 11492250. DOI: 10.1016/j.heliyon.2024.e38831.


Cardiac Morbidity and Mortality in Patients with Sarcoma: A Population-Based Study.

Alanazi R, Aljizeeri A, Alsaileek A, Alrashid A, Alolayan A, Alkaiyat M Clin Med Insights Oncol. 2024; 18:11795549241237703.

PMID: 38558879 PMC: 10979535. DOI: 10.1177/11795549241237703.


The burden and predictors of venous thromboembolic diseases in patients with multiple primary malignancies.

Alhamadh M, Alanazi R, Alqirnas M, Alhabeeb A, Chachar Y, Alkaiyat M Cancer Rep (Hoboken). 2022; 6(3):e1742.

PMID: 36314077 PMC: 10026306. DOI: 10.1002/cnr2.1742.

References
1.
Phillippe H . Overview of venous thromboembolism. Am J Manag Care. 2018; 23(20 Suppl):S376-S382. View

2.
Pritchard K, Paterson A, Paul N, Zee B, Fine S, Pater J . Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996; 14(10):2731-7. DOI: 10.1200/JCO.1996.14.10.2731. View

3.
Cook D, McMullin J, Hodder R, Heule M, Pinilla J, Dodek P . Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey. Crit Care. 2001; 5(6):336-42. PMC: 83855. DOI: 10.1186/cc1066. View

4.
Mussbacher M, Salzmann M, Brostjan C, Hoesel B, Schoergenhofer C, Datler H . Cell Type-Specific Roles of NF-κB Linking Inflammation and Thrombosis. Front Immunol. 2019; 10:85. PMC: 6369217. DOI: 10.3389/fimmu.2019.00085. View

5.
Dahm A . Cancer and Thrombosis: New Treatments, New Challenges. Med Sci (Basel). 2021; 9(2). PMC: 8293316. DOI: 10.3390/medsci9020041. View